this is hero image

The Eversense PASS™ Program offers savings on THE ONLY long-term CGM System with 6 months of real-time glucose readings.

Payment Assistance and Simple Savings

To help eligible people with diabetes more affordably access the Eversense E3 CGM System

 $99 for 6 months


Eligible individuals can experience EVERSENSE E3 CGM for only $99, now and in the future.

That includes the patient’s initial and ongoing sensor and sensor/transmitter combinations – which is
equivalent to an average monthly cost of $16.50!

Eligibility Overview


  • Eligibility: To be eligible, the patient must have a commercial insurance plan with or without coverage for the EVERSENSE® E3 CGM. The patient must also meet medical coverage criteria for CGM as indicated by their insurance provider.
  • Exclusions: Government insurance as primary or secondary coverage (i.e., Medicare, Medicare Advantage, Medicaid, and Tri-Care) or insurance plans that require purchase directly from HCPs (Health Care Professionals) via global payment.

Get Started with Eversense

If you're on insulin, you might greatly benefit from Eversense. Whether you’re ready to get started now or just have additional questions about Eversense, an Ascensia Diabetes Care (Ascensia) representative can help. Fill in and submit the form below and we’ll be in touch via phone or text.  We’ll also send you additional information about Eversense to help with your decision.
All fields marked with an asterisk (*) are required.

Diabetes Type*
Number of Daily Insulin Injections*
HAVE YOU USED A CGM DEVICE BEFORE?
DO YOU CURRENTLY USE A BLOOD GLUCOSE METER?
PREFERRED LANGUAGE
PREFERRED METHOD OF COMMUNICATION

ON A SCALE OF 1 - 5, HOW READY ARE YOU TO GET STARTED?

 Offer does not apply to the insertion and removal procedures. The Eversense PASS Program has limitations on eligibility.
See website (bit.ly/EversensePass) for more details. Ascensia Diabetes Care reserves the right to change or terminate this program at any time without notice. The program benefit is capped per transaction. There may be instances in which out-of-pocket costs exceed what is detailed in the offer.

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more. For safety information click here.

Eversense, Eversense E3 Continuous Glucose Monitoring and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, and the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.



Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.